Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of L-Nio. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | ARG2 | P78540 | 4/20 | 0.49 |
| ▸ | NOS2 | P35228 | 6/20 | 0.47 |
| ▸ | NOS1 | P29475 | 5/20 | 0.47 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GGT1 | P19440 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Nio SCHEMBL676368 | 1.00 | OTC (0.53) | OTCARG2NOS2NOS1NOS3 | |
| L-Nio SCHEMBL7662264 | 1.00 | OTC (0.53) | OTCARG2NOS2NOS1NOS3 | |
| L-Nio SCHEMBL1320518 | 1.00 | OTC (0.53) | OTCARG2NOS2NOS1NOS3 | |
| L-Nio SCHEMBL1320520 | 1.00 | OTC (0.53) | OTCARG2NOS2NOS1NOS3 | |
| L-Nio SCHEMBL29156210 | 1.00 | OTC (0.53) | OTCARG2NOS2NOS1NOS3 | |
| L-Nio SCHEMBL4424485 | 0.98 | OTC (0.54) | OTCARG2NOS2NOS1NOS3 | |
| L-Nio SCHEMBL5287105 | 0.98 | OTC (0.54) | OTCARG2NOS2NOS1NOS3 | |
| L-Nio SCHEMBL1569333 | 0.98 | OTC (0.54) | OTCARG2NOS2NOS1NOS3 | |
| L-Nil SCHEMBL1321685 | 0.95 | ARG2 (0.51) | OTCARG2NOS2NOS1NOS3 | |
| L-Nil SCHEMBL7974005 | 0.95 | ARG2 (0.51) | OTCARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544406-B2 | Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240166994-A1 | OLIGODENDROCYTE PROGENITOR CELL COMPOSITIONS | ASTERIAS BIOTHERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11920155-B2 | Oligodendrocyte progenitor cell compositions | ASTERIAS BIOTHERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-116121189-A | Oligodendrocyte progenitor cell compositions | 阿斯特利亚斯生物治疗股份公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11439675-B2 | Method for treating damage induced by sleep deprivation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220241345-A1 | INDUCED PLURIPOTENT STEM CELL DERIVED GLIAL ENRICHED PROGENITOR CELLS FOR THE TREATMENT OF WHITE MATTER STROKE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3956021-A1 | METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2 | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-114072205-A | Method of treating hypertension with TIE-2 activator | 视点制药公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20200352914-A1 | METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2 | EyePoint Pharmaceuticals, Inc. | 2020-11-12 | — | — | US | disclosed |
| WO-2020214851-A1 | METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2 | Aerpio Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20120276220-A1 | Method of Treating Hepatitis | YALE UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120156244-A1 | Nasal Compositions and Uses Thereof | ALPHA SYNERGY DEVELOPMENT INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110257188-A1 | Compositions and methods for the treatment of nasal conditions | PS THERAPIES LTD (BB) | 2011-10-20 | — | — | US | disclosed |
| US-20110160214-A1 | Compositions and methods for eye whitening | Alpha Synergy Development, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110003823-A1 | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage | Alpha Synergy Development, Inc. | 2011-01-06 | — | — | US | disclosed |
| US-20090306153-A1 | SYNTHESIS AND USE OF NOVEL INHIBITORS AND INACTIVATORS OF PROTEIN ARGININE DEIMINASES | UNIVERSITY OF SOUTH CAROLINA (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080171021-A1 | PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20050074448-A1 | Increasing nitric oxide production; nitric oxide synthase havingTAT protein transduction domain; vascular diseases | THE CURATOR SOF THE UNIVERSITY OF MISSOURI | 2005-04-07 | — | — | US | disclosed |
| US-20040131703-A1 | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | disclosed |
| US-20040052866-A1 | Methods of treating hepatitis | PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439675-B2 | Method for treating damage induced by sleep deprivation | SI, CRY2, PER2 | OTC 314/4885ARG2 77/4885NOS2 357/4885 |
| US-20200352914-A1 | METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2 | TIE1, TEK, VASP | OTC 1320/4885ARG2 337/4885NOS2 135/4885 |
| US-12544406-B2 | Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke | GFRA3, NES, DCX | OTC 1039/4885ARG2 983/4885NOS2 722/4885 |
| US-20090306153-A1 | SYNTHESIS AND USE OF NOVEL INHIBITORS AND INACTIVATORS OF PROTEIN ARGININE DEIMINASES | PADI1, PADI4, PADI2 | OTC 271/4885ARG2 42/4885NOS2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.